Cipla Limited

LIC increased its stake in Cipla from 9.62% to 9.75%, buying 1,091,640 shares worth ₹157.02 Cr at ₹1437.90 apiece.

A leading pharmaceutical manufacturer, Cipla develops and markets branded and generic formulations alongside active pharmaceutical ingredients across multiple therapeutic areas. Established in 1935, the company operates manufacturing facilities across India and internationally, serving both domestic and global markets. Cipla's distinctive strength lies in its integrated business model combining formulation development with API production, enabling cost-efficient drug manufacturing, distribution, and accessibility to patients worldwide.

India's largest domestic institutional investor with over Rs 56 lakh crore in total AUM, of which roughly Rs 15 lakh crore sits in listed equities. Holds stakes in virtually every major listed Indian company. When LIC builds or exits a position, it moves markets. Government-owned and mandated to invest policyholder funds in Indian equities and bonds, making it the ultimate long-only, long-term India bull.